Age Related Macular Degeneration Market Size, Share, and Trends Analysis Report
CAGR :
| Market Size 2023 (Base Year) | USD 11.6 Billion |
| Market Size 2032 (Forecast Year) | USD 20.65 Billion |
| CAGR | 6.62% |
| Forecast Period | 2024 - 2032 |
| Historical Period | 2018 - 2023 |
Age Related Macular Degeneration Market Insights
According to Market Research Store, the global age related macular degeneration market size was valued at around USD 11.6 billion in 2023 and is estimated to reach USD 20.65 billion by 2032, to register a CAGR of approximately 6.62% in terms of revenue during the forecast period 2024-2032.
The age related macular degeneration report provides a comprehensive analysis of the market, including its size, share, growth trends, revenue details, and other crucial information regarding the target market. It also covers the drivers, restraints, opportunities, and challenges till 2032.
To Get more Insights, Request a Free Sample
Global Age Related Macular Degeneration Market: Overview
Age-Related Macular Degeneration (AMD) is a chronic eye condition and a leading cause of vision loss among individuals aged 50 and older. It affects the macula, the central part of the retina responsible for sharp, straight-ahead vision needed for tasks like reading, driving, and recognizing faces. AMD progresses in two main forms: dry AMD, which is more common and characterized by the gradual thinning of the macula, and wet AMD, which involves the growth of abnormal blood vessels under the retina that can leak and cause rapid vision loss. While AMD doesn’t lead to complete blindness, it can severely impair central vision.
Key Highlights
- The age related macular degeneration market is anticipated to grow at a CAGR of 6.62% during the forecast period.
- The global age related macular degeneration market was estimated to be worth approximately USD 11.6 billion in 2023 and is projected to reach a value of USD 20.65 billion by 2032.
- The growth of the age related macular degeneration market is being driven by rising geriatric populations, increasing awareness of eye health, and advances in treatment technologies.
- Based on the product type, the Light Therapy Devices segment is growing at a high rate and is projected to dominate the market.
- On the basis of treatment type, the Skin Tightening segment is projected to swipe the largest market share.
- In terms of end-user, the Hospitals and Aesthetic Clinics segment is expected to dominate the market.
- By region, North America is expected to dominate the global market during the forecast period.
Age Related Macular Degeneration Market: Dynamics
Key Growth Drivers:
- Rising Geriatric Population: The global increase in elderly individuals is leading to a higher prevalence of AMD, which primarily affects people over 50, thereby driving demand for effective treatments.
- Advancements in Treatment Options: Continuous innovations such as anti-VEGF therapies, sustained-release drug delivery, and gene therapy are improving patient outcomes and expanding the treatment landscape.
- Growing Awareness & Screening Programs: Public health initiatives and campaigns focused on early detection and regular eye check-ups are contributing to early diagnosis and treatment adoption.
- Increased Healthcare Expenditure: Governments and private sectors are investing more in ophthalmology, facilitating better access to care, especially in emerging markets.
Restraints:
- High Cost of AMD Treatments: Treatments, especially biologic drugs like anti-VEGF injections, are expensive and not always fully covered by insurance, limiting access in lower-income populations.
- Limited Availability in Developing Regions: In many low- and middle-income countries, advanced diagnostic tools and therapies are still not widely accessible due to poor healthcare infrastructure.
Opportunities:
- Emerging Markets Adoption: Rapid urbanization and improving healthcare systems in regions like Asia Pacific and Latin America present opportunities for market expansion and increased AMD care penetration.
- Development of Long-Acting Therapies: Research into treatments requiring fewer injections or visits could significantly improve patient compliance and reduce treatment burden.
- Digital Health Integration: Use of telemedicine, AI-powered diagnostic tools, and electronic health records can enhance early detection and personalized treatment plans.
Challenges:
- Low Patient Compliance: AMD treatments often require frequent injections and follow-ups, which can be burdensome for elderly patients and may lead to inconsistent treatment.
- Regulatory and Reimbursement Barriers: Complex approval processes and limited reimbursement policies in certain regions can delay the availability of innovative therapies.
- Lack of Curative Treatment: Most current treatments manage symptoms but do not reverse or cure AMD, keeping the focus on long-term disease management rather than resolution.
Age Related Macular Degeneration Market: Report Scope
This report thoroughly analyzes the Age Related Macular Degeneration Market, exploring its historical trends, current state, and future projections. The market estimates presented result from a robust research methodology, incorporating primary research, secondary sources, and expert opinions. These estimates are influenced by the prevailing market dynamics as well as key economic, social, and political factors. Furthermore, the report considers the impact of regulations, government expenditures, and advancements in research and development on the market. Both positive and negative shifts are evaluated to ensure a comprehensive and accurate market outlook.
| Report Attributes | Report Details |
|---|---|
| Report Name | Age Related Macular Degeneration Market |
| Market Size in 2023 | USD 11.6 Billion |
| Market Forecast in 2032 | USD 20.65 Billion |
| Growth Rate | CAGR of 6.62% |
| Number of Pages | 177 |
| Key Companies Covered | Valeant Pharmaceuticals International, Inc., Novartis International AG, Ophthotech Corporation, Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd, Bayer AG, Adverum Biotechnologies, Inc., Regeneron Pharmaceuticals, Inc., Amgen Inc., Gilead Sciences Inc., Apellis Pharmeceuticals, Inc., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc., Neurotech Pharmaceuticals Inc., and Alimera Sciences Inc., and Others |
| Segments Covered | By Product Type, By Drug Type, By Route Of Administration, By Age Group Type, By, By And End-User, And By Region |
| Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
| Base Year | 2023 |
| Historical Year | 2018 to 2023 |
| Forecast Year | 2024 to 2032 |
| Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
Age Related Macular Degeneration Market: Segmentation Insights
The global age related macular degeneration market is divided by product type, treatment type, end-user, and region.
Based on product type, the global age related macular degeneration market is divided into laser skin resurfacing devices, micro-needling products, nonsurgical skin tightening devices, light therapy device, and others. Light Therapy Devices represent the most dominant product type segment. These devices are increasingly used in photobiomodulation therapy, a non-invasive treatment that uses specific wavelengths of light to reduce inflammation and oxidative stress in retinal cells, helping to slow the progression of AMD. Their non-surgical nature, ease of use, and emerging clinical evidence supporting efficacy make them a preferred option, especially for patients in the early to intermediate stages of AMD.
On the basis of treatment type, the global age related macular degeneration market is bifurcated into laser lipo, body contouring, skin tightening, instant rejuvenation, and others. Skin Tightening emerges as the most dominant segment, though primarily in the context of aging-related aesthetic and periorbital treatments rather than core AMD therapy. As AMD primarily affects older adults, complementary skin tightening treatments around the eyes are increasingly sought after by patients aiming to maintain a youthful appearance. Non-invasive skin tightening options using radiofrequency or ultrasound are especially popular due to their minimal downtime and safety for the sensitive eye area.
Based on end-user, the global age related macular degeneration market is divided into medical spas and beauty salons, hospitals and aesthetic clinics, home settings, and others. Hospitals and Aesthetic Clinics represent the most dominant segment. These facilities are equipped with advanced diagnostic technologies, ophthalmologists, and trained medical professionals who can administer specialized treatments such as anti-VEGF injections, light therapy, or any emerging AMD therapies. Aesthetic clinics also play a role in addressing age-related periorbital changes, complementing AMD management with cosmetic care when needed. The integration of medical expertise and comprehensive treatment capabilities makes this segment the primary point of care for AMD patients.
Age Related Macular Degeneration Market: Regional Insights
- North America is expected to dominates the global market
North America is the most dominant region in the Age-Related Macular Degeneration market, primarily driven by the presence of a large aging population, advanced healthcare infrastructure, and high awareness levels regarding early detection and treatment of eye diseases. The U.S. leads the regional market due to its high adoption rate of innovative therapies, strong presence of pharmaceutical companies, and continuous investments in clinical research. Government reimbursement policies and widespread use of anti-VEGF drugs further contribute to North America's leadership in the AMD market.
Europe follows closely behind and maintains a strong position in the age related macular degeneration market due to its aging demographic and robust public healthcare systems. Countries like Germany, the United Kingdom, and France exhibit significant market activity, supported by early screening programs and established guidelines for AMD treatment. Additionally, the region benefits from well-structured clinical trials and regulatory frameworks that accelerate the approval and availability of novel therapeutics. Collaborations between biotech firms and research organizations also help drive innovation in this region.
Asia Pacific is an emerging and rapidly expanding market for AMD, supported by growing elderly populations in countries like Japan, China, and South Korea. While historically underserved, the region is experiencing increasing healthcare expenditure, improved access to ophthalmic care, and a rising prevalence of lifestyle diseases like diabetes that heighten the risk of age related macular degeneration. Urbanization, growing awareness about retinal disorders, and efforts by governments to upgrade healthcare infrastructure are expected to boost regional market growth significantly in the coming years.
Latin America is showing gradual growth in the age related macular degeneration market, primarily driven by urban centers in Brazil, Mexico, and Argentina. While access to advanced treatments is improving, disparities remain due to economic constraints and uneven healthcare access. The region is increasingly adopting modern diagnostic technologies, and pharmaceutical companies are gradually expanding their reach through strategic partnerships and public-private collaborations, especially in metropolitan areas.
Middle East and Africa hold the smallest share in the global age related macular degeneration market due to limited awareness, low screening rates, and underdeveloped healthcare infrastructure in many parts of the region. However, countries like the UAE, Saudi Arabia, and South Africa are witnessing improvements through government-led healthcare reforms and rising private sector investment in ophthalmology. Increased focus on early diagnosis and the introduction of international healthcare providers are expected to slowly enhance market penetration over time.
Age Related Macular Degeneration Market: Competitive Landscape
The report provides an in-depth analysis of companies operating in the age related macular degeneration market, including their geographic presence, business strategies, product offerings, market share, and recent developments. This analysis helps to understand market competition.
Some of the major players in the global age related macular degeneration market include:
- Valeant Pharmaceuticals International Inc.
- Novartis International AG
- Ophthotech Corporation
- Pfizer Inc.
- Kubota Pharmaceutical Holdings Co. Ltd
- Bayer AG
- Adverum Biotechnologies Inc.
- Regeneron Pharmaceuticals Inc.
- Amgen Inc.
- Gilead Sciences Inc.
- Apellis Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
- Bausch Health Companies Inc.
- Neurotech Pharmaceuticals Inc.
- Alimera Sciences Inc.
The global age related macular degeneration market is segmented as follows:
By Product Type
- Laser Skin Resurfacing Devices
- Micro-Needling Products
- Nonsurgical Skin Tightening Devices
- Light Therapy Device
- Others
By Treatment Type
- Laser Lipo
- Body Contouring
- Skin Tightening
- Instant Rejuvenation
- Others
By End-User
- Medical Spas and Beauty Salons
- Hospitals and Aesthetic Clinics
- Home Settings
- Others
By Region
- North America
- U.S.
- Canada
- Europe
- U.K.
- France
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- The Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East Africa
Frequently Asked Questions
Table Of Content
- Chapter 1 Executive Summary
- 1.1. Introduction of Age Related Macular Degeneration
- 1.2. Global Age Related Macular Degeneration Market, 2019 & 2026 (USD Million)
- 1.3. Global Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 1.4. Global Age Related Macular Degeneration Market Absulute Revenue Opportunity, 2016 – 2026 (USD Million)
- 1.5. Global Age Related Macular Degeneration Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)
- Chapter 2 Age Related Macular Degeneration Market – Product Type Analysis
- 2.1. Global Age Related Macular Degeneration Market – Product Type Overview
- 2.2. Global Age Related Macular Degeneration Market Share, by Product Type, 2019 & 2026 (USD Million)
- 2.3. Dry AMD
- 2.3.1. Global Dry AMD Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 2.4. Wet AMD
- 2.4.1. Global Wet AMD Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- Chapter 3 Age Related Macular Degeneration Market – Drug Type Analysis
- 3.1. Global Age Related Macular Degeneration Market – Drug Type Overview
- 3.2. Global Age Related Macular Degeneration Market Share, by Drug Type, 2019 & 2026 (USD Million)
- 3.3. Eylea
- 3.3.1. Global Eylea Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 3.4. Lucentis
- 3.4.1. Global Lucentis Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 3.5. Avastin
- 3.5.1. Global Avastin Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 3.6. Others
- 3.6.1. Global Others Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- Chapter 4 Age Related Macular Degeneration Market – Age Group Type Analysis
- 4.1. Global Age Related Macular Degeneration Market – Age Group Type Overview
- 4.2. Global Age Related Macular Degeneration Market Share, by Age Group Type, 2019 & 2026 (USD Million)
- 4.3. Between 40 - 50 Years
- 4.3.1. Global Between 40 - 50 Years Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 4.4. Between 50 - 60 Years
- 4.4.1. Global Between 50 - 60 Years Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 4.5. Between 60 - 70 Years
- 4.5.1. Global Between 60 - 70 Years Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 4.6. Above 70 Years
- 4.6.1. Global Above 70 Years Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- Chapter 5 Age Related Macular Degeneration Market – Route Of Administration Analysis
- 5.1. Global Age Related Macular Degeneration Market – Route Of Administration Overview
- 5.2. Global Age Related Macular Degeneration Market Share, by Route Of Administration, 2019 & 2026 (USD Million)
- 5.3. Intravitreal
- 5.3.1. Global Intravitreal Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 5.4. Intravenous
- 5.4.1. Global Intravenous Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- Chapter 6 Age Related Macular Degeneration Market – End-User Analysis
- 6.1. Global Age Related Macular Degeneration Market – End-User Overview
- 6.2. Global Age Related Macular Degeneration Market Share, by End-User, 2019 & 2026 (USD Million)
- 6.3. Hospital & Clinics
- 6.3.1. Global Hospital & Clinics Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 6.4. Academic Research Institutes
- 6.4.1. Global Academic Research Institutes Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 6.5. Diagnostic Centers
- 6.5.1. Global Diagnostic Centers Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- Chapter 7 Age Related Macular Degeneration Market – Regional Analysis
- 7.1. Global Age Related Macular Degeneration Market Regional Overview
- 7.2. Global Age Related Macular Degeneration Market Share, by Region, 2019 & 2026 (USD Million)
- 7.3. North America
- 7.3.1. North America Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.3.1.1. North America Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
- 7.3.2. North America Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
- 7.3.2.1. North America Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
- 7.3.3. North America Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
- 7.3.3.1. North America Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
- 7.3.4. North America Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
- 7.3.4.1. North America Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
- 7.3.5. North America Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
- 7.3.5.1. North America Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
- 7.3.6. North America Age Related Macular Degeneration Market, by End-User, 2016 – 2026
- 7.3.6.1. North America Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
- 7.3.7. U.S.
- 7.3.7.1. U.S. Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.3.8. Canada
- 7.3.8.1. Canada Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.3.1. North America Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.4. Europe
- 7.4.1. Europe Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.4.1.1. Europe Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
- 7.4.2. Europe Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
- 7.4.2.1. Europe Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
- 7.4.3. Europe Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
- 7.4.3.1. Europe Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
- 7.4.4. Europe Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
- 7.4.4.1. Europe Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
- 7.4.5. Europe Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
- 7.4.5.1. Europe Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
- 7.4.6. Europe Age Related Macular Degeneration Market, by End-User, 2016 – 2026
- 7.4.6.1. Europe Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
- 7.4.7. Germany
- 7.4.7.1. Germany Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.4.8. France
- 7.4.8.1. France Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.4.9. U.K.
- 7.4.9.1. U.K. Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.4.10. Italy
- 7.4.10.1. Italy Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.4.11. Spain
- 7.4.11.1. Spain Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.4.12. Rest of Europe
- 7.4.12.1. Rest of Europe Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.4.1. Europe Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Asia Pacific Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.5.1.1. Asia Pacific Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
- 7.5.2. Asia Pacific Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
- 7.5.2.1. Asia Pacific Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
- 7.5.3. Asia Pacific Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
- 7.5.3.1. Asia Pacific Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
- 7.5.4. Asia Pacific Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
- 7.5.4.1. Asia Pacific Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
- 7.5.5. Asia Pacific Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
- 7.5.5.1. Asia Pacific Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
- 7.5.6. Asia Pacific Age Related Macular Degeneration Market, by End-User, 2016 – 2026
- 7.5.6.1. Asia Pacific Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
- 7.5.7. China
- 7.5.7.1. China Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.5.8. Japan
- 7.5.8.1. Japan Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.5.9. India
- 7.5.9.1. India Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.5.10. South Korea
- 7.5.10.1. South Korea Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.5.11. South-East Asia
- 7.5.11.1. South-East Asia Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.5.12. Rest of Asia Pacific
- 7.5.12.1. Rest of Asia Pacific Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.5.1. Asia Pacific Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.6. Latin America
- 7.6.1. Latin America Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.6.1.1. Latin America Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
- 7.6.2. Latin America Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
- 7.6.2.1. Latin America Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
- 7.6.3. Latin America Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
- 7.6.3.1. Latin America Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
- 7.6.4. Latin America Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
- 7.6.4.1. Latin America Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
- 7.6.5. Latin America Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
- 7.6.5.1. Latin America Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
- 7.6.6. Latin America Age Related Macular Degeneration Market, by End-User, 2016 – 2026
- 7.6.6.1. Latin America Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
- 7.6.7. Brazil
- 7.6.7.1. Brazil Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.6.8. Mexico
- 7.6.8.1. Mexico Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.6.9. Rest of Latin America
- 7.6.9.1. Rest of Latin America Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.6.1. Latin America Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.7. The Middle-East and Africa
- 7.7.1. The Middle-East and Africa Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.7.1.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
- 7.7.2. The Middle-East and Africa Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
- 7.7.2.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
- 7.7.3. The Middle-East and Africa Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
- 7.7.3.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
- 7.7.4. The Middle-East and Africa Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
- 7.7.4.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
- 7.7.5. The Middle-East and Africa Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
- 7.7.5.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
- 7.7.6. The Middle-East and Africa Age Related Macular Degeneration Market, by End-User, 2016 – 2026
- 7.7.6.1. The Middle-East and Africa Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
- 7.7.7. GCC Countries
- 7.7.7.1. GCC Countries Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.7.8. South Africa
- 7.7.8.1. South Africa Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.7.9. Rest of Middle-East Africa
- 7.7.9.1. Rest of Middle-East Africa Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- 7.7.1. The Middle-East and Africa Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
- Chapter 8 Age Related Macular Degeneration Market – Competitive Landscape
- 8.1. Competitor Market Share – Revenue
- 8.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
- 8.3. Strategic Developments
- 8.3.1. Acquisitions and Mergers
- 8.3.2. New Products
- 8.3.3. Research & Development Activities
- Chapter 9 Company Profiles
- 9.1. Valeant Pharmaceuticals International, Inc.
- 9.1.1. Company Overview
- 9.1.2. Product/Service Portfulio
- 9.1.3. Valeant Pharmaceuticals International, Inc. Sales, Revenue, and Gross Margin
- 9.1.4. Valeant Pharmaceuticals International, Inc. Revenue and Growth Rate
- 9.1.5. Valeant Pharmaceuticals International, Inc. Market Share
- 9.1.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.2. Novartis International AG
- 9.2.1. Company Overview
- 9.2.2. Product/Service Portfulio
- 9.2.3. Novartis International AG Sales, Revenue, and Gross Margin
- 9.2.4. Novartis International AG Revenue and Growth Rate
- 9.2.5. Novartis International AG Market Share
- 9.2.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.3. Ophthotech Corporation
- 9.3.1. Company Overview
- 9.3.2. Product/Service Portfulio
- 9.3.3. Ophthotech Corporation Sales, Revenue, and Gross Margin
- 9.3.4. Ophthotech Corporation Revenue and Growth Rate
- 9.3.5. Ophthotech Corporation Market Share
- 9.3.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.4. Pfizer Inc.
- 9.4.1. Company Overview
- 9.4.2. Product/Service Portfulio
- 9.4.3. Pfizer Inc. Sales, Revenue, and Gross Margin
- 9.4.4. Pfizer Inc. Revenue and Growth Rate
- 9.4.5. Pfizer Inc. Market Share
- 9.4.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.5. Kubota Pharmaceutical Huldings Co. Ltd
- 9.5.1. Company Overview
- 9.5.2. Product/Service Portfulio
- 9.5.3. Kubota Pharmaceutical Huldings Co. Ltd Sales, Revenue, and Gross Margin
- 9.5.4. Kubota Pharmaceutical Huldings Co. Ltd Revenue and Growth Rate
- 9.5.5. Kubota Pharmaceutical Huldings Co. Ltd Market Share
- 9.5.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.6. Bayer AG
- 9.6.1. Company Overview
- 9.6.2. Product/Service Portfulio
- 9.6.3. Bayer AG Sales, Revenue, and Gross Margin
- 9.6.4. Bayer AG Revenue and Growth Rate
- 9.6.5. Bayer AG Market Share
- 9.6.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.7. Adverum Biotechnulogies, Inc.
- 9.7.1. Company Overview
- 9.7.2. Product/Service Portfulio
- 9.7.3. Adverum Biotechnulogies, Inc. Sales, Revenue, and Gross Margin
- 9.7.4. Adverum Biotechnulogies, Inc. Revenue and Growth Rate
- 9.7.5. Adverum Biotechnulogies, Inc. Market Share
- 9.7.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.8. Regeneron Pharmaceuticals, Inc.
- 9.8.1. Company Overview
- 9.8.2. Product/Service Portfulio
- 9.8.3. Regeneron Pharmaceuticals, Inc. Sales, Revenue, and Gross Margin
- 9.8.4. Regeneron Pharmaceuticals, Inc. Revenue and Growth Rate
- 9.8.5. Regeneron Pharmaceuticals, Inc. Market Share
- 9.8.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.9. Amgen Inc.
- 9.9.1. Company Overview
- 9.9.2. Product/Service Portfulio
- 9.9.3. Amgen Inc. Sales, Revenue, and Gross Margin
- 9.9.4. Amgen Inc. Revenue and Growth Rate
- 9.9.5. Amgen Inc. Market Share
- 9.9.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.10. Gilead Sciences Inc.
- 9.10.1. Company Overview
- 9.10.2. Product/Service Portfulio
- 9.10.3. Gilead Sciences Inc. Sales, Revenue, and Gross Margin
- 9.10.4. Gilead Sciences Inc. Revenue and Growth Rate
- 9.10.5. Gilead Sciences Inc. Market Share
- 9.10.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.11. Apellis Pharmeceuticals, Inc.
- 9.11.1. Company Overview
- 9.11.2. Product/Service Portfulio
- 9.11.3. Apellis Pharmeceuticals, Inc. Sales, Revenue, and Gross Margin
- 9.11.4. Apellis Pharmeceuticals, Inc. Revenue and Growth Rate
- 9.11.5. Apellis Pharmeceuticals, Inc. Market Share
- 9.11.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.12. F. Hoffmann-La Roche Ltd.
- 9.12.1. Company Overview
- 9.12.2. Product/Service Portfulio
- 9.12.3. F. Hoffmann-La Roche Ltd. Sales, Revenue, and Gross Margin
- 9.12.4. F. Hoffmann-La Roche Ltd. Revenue and Growth Rate
- 9.12.5. F. Hoffmann-La Roche Ltd. Market Share
- 9.12.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.13. Bausch Health Companies Inc.
- 9.13.1. Company Overview
- 9.13.2. Product/Service Portfulio
- 9.13.3. Bausch Health Companies Inc. Sales, Revenue, and Gross Margin
- 9.13.4. Bausch Health Companies Inc. Revenue and Growth Rate
- 9.13.5. Bausch Health Companies Inc. Market Share
- 9.13.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.14. Neurotech Pharmaceuticals Inc.
- 9.14.1. Company Overview
- 9.14.2. Product/Service Portfulio
- 9.14.3. Neurotech Pharmaceuticals Inc. Sales, Revenue, and Gross Margin
- 9.14.4. Neurotech Pharmaceuticals Inc. Revenue and Growth Rate
- 9.14.5. Neurotech Pharmaceuticals Inc. Market Share
- 9.14.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.15. Alimera Sciences Inc.
- 9.15.1. Company Overview
- 9.15.2. Product/Service Portfulio
- 9.15.3. Alimera Sciences Inc. Sales, Revenue, and Gross Margin
- 9.15.4. Alimera Sciences Inc. Revenue and Growth Rate
- 9.15.5. Alimera Sciences Inc. Market Share
- 9.15.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.16. Others
- 9.16.1. Company Overview
- 9.16.2. Product/Service Portfulio
- 9.16.3. Others Sales, Revenue, and Gross Margin
- 9.16.4. Others Revenue and Growth Rate
- 9.16.5. Others Market Share
- 9.16.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
- 9.1. Valeant Pharmaceuticals International, Inc.
- Chapter 10 Age Related Macular Degeneration — Industry Analysis
- 10.1. Introduction and Taxonomy
- 10.2. Age Related Macular Degeneration Market – Key Trends
- 10.2.1. Market Drivers
- 10.2.2. Market Restraints
- 10.2.3. Market Opportunities
- 10.3. Value Chain Analysis
- 10.4. Key Mandates and Regulations
- 10.5. Technulogy Roadmap and Timeline
- 10.6. Age Related Macular Degeneration Market – Attractiveness Analysis
- 10.6.1. By Product Type
- 10.6.2. By Drug Type
- 10.6.3. By Age Group Type
- 10.6.4. By Route Of Administration
- 10.6.5. By End-User
- 10.6.6. By Region
- Chapter 11 Industrial Chain, Sourcing Strategy, and Downstream Buyers
- 11.1. Age Related Macular Degeneration Industrial Chain Analysis
- 11.2. Downstream Buyers
- 11.3. Distributors/Traders List
- Chapter 12 Marketing Strategy Analysis
- 12.1. Marketing Channel
- 12.2. Direct Marketing
- 12.3. Indirect Marketing
- 12.4. Marketing Channel Development Trends
- 12.5. Economic/Pulitical Environmental Change
- Chapter 13 Report Conclusion & Key Insights
- 13.1. Key Insights from Primary Interviews & Surveys Respondents
- 13.2. Key Takeaways from Analysts, Consultants, and Industry Leaders
- Chapter 14 Research Approach & Methodulogy
- 14.1. Report Description
- 14.2. Research Scope
- 14.3. Research Methodulogy
- 14.3.1. Secondary Research
- 14.3.2. Primary Research
- 14.3.3. Statistical Models
- 14.3.3.1. Company Share Analysis Model
- 14.3.3.2. Revenue Based Modeling
- 14.3.4. Research Limitations
Inquiry For Buying
Age Related Macular Degeneration
Request Sample
Age Related Macular Degeneration
